Searches / J Assoc Physicians India [JOURNAL]

J Assoc Physicians India [JOURNAL]

Sun 200 papers
RSS

Profile of Acute Kidney Injury in Patients Undergoing Cardiac Surgery with Use of Cardiopulmonary Bypass Machine.

Ghosh I, Agrahari D, Sangha SS … +10 more , Behera V, Dogra PM, Iyengar S, Varghese P, Joshi R, Menon AS, Srivastava S, Akal RS, Yadav RK, Mohakuda SS

J Assoc Physicians India · 2026 Feb · PMID 41818071 · Publisher ↗

INTRODUCTION: Acute kidney injury (AKI) is a well-known serious complication of cardiopulmonary bypass (CPB) surgery and one of the significant risk factors for mortality, prolonged hospital stay, and additional cost. Pa... INTRODUCTION: Acute kidney injury (AKI) is a well-known serious complication of cardiopulmonary bypass (CPB) surgery and one of the significant risk factors for mortality, prolonged hospital stay, and additional cost. Patients having preexisting kidney dysfunction are more likely to develop AKI in the perioperative period. The complexity of CPB surgery often leads to AKI. Mechanisms of AKI include kidney hypoperfusion due to low-pressure blood flow. The nonpulsatile perfusion of the kidney, hypothermia, and inflammatory milieu, which causes afferent arteriolar constriction, contribute to AKI. The early postoperative period is characterized by a low cardiac output state, which gradually surpasses kidney compensatory mechanisms and filtration reserve. Various indigenous and infused vasopressors cause markedly elevated afferent arteriolar resistance, leading to a drop in glomerular filtration rate (GFR). Several studies have assessed the value of risk factors and their association with AKI after cardiac surgery. The evidence was mixed, with some showing a positive association. With an aim to clarify this relationship further, especially in the Indian population, we tried to study the incidence and clinical profile of AKI and its correlation with functional and clinical outcomes. We also tried to look for any diagnostic markers of AKI in the setting of cardiac surgery. METHODOLOGY: The study was conducted among patients attending the Department of General Medicine and Cardiology at a tertiary care hospital in Delhi. It was a prospective longitudinal observational study conducted between March 2022 and February 2024. Around 200 patients underwent cardiac surgery using a cardiopulmonary bypass machine at the study center during the study period. History, including comorbidities such as transient ischemic attacks, previous stroke, coronary artery disease, diabetes mellitus, hypertension, chronic obstructive pulmonary disease (COPD), and complete physical examination, were recorded. Patients were followed up preoperatively and postoperatively up to day 28. Preoperative details such as hemoglobin, serum creatinine, blood transfusion, and urine output were recorded. Intraoperative details such as duration of surgery, ACC (aortic cross-clamp) duration, hypotension, vasopressor use, and re-exploration were recorded. Postoperative findings such as urine output and serial kidney function tests on day 3, day 7, and day 28 were documented. RESULTS: Among 200 subjects, 99 patients had hypertension, and 70 patients developed AKI. Older age (>60 years) was significantly associated with AKI (-value 0.04367). Comorbid conditions such as T2DM, hypertension, dyslipidemia, and COPD were significantly associated with AKI as compared to those without comorbidities (Chi-squared test, -value < 0.0001). In the study, there was no association between the type of surgery and the development of AKI (Chi-squared test, -value 0.07). There was no relationship between AKI severity and cardiopulmonary bypass (CPB) duration. Similarly, there was no association between the severity of AKI and ACC duration. Intraoperative hypotension was significantly associated with AKI. About 53% of hypotensive patients developed AKI during surgery as compared to 19.44% of normotensive patients (-value < 0.0001, Chi-squared test). AKI was linked with a significantly prolonged hospital stay. A prolonged stay of >3 weeks was seen in 8.5% (6 out of 70) of patients who developed AKI as compared to 2.3% (3 out of 130) of patients without AKI. Most patients with AKI (57%) recovered within 1 week, and 24.28% recovered between 1 and 4 weeks. In the study, 8 patients (11.2%) developed acute kidney disease (AKD), and 5 patients (7%) died. CONCLUSION: This prospective study concluded that AKI is a common complication in the perioperative period of cardiopulmonary bypass surgery. Older age, comorbid conditions, and intraoperative hypotension were significantly associated with AKI. AKI was linked with extended hospital stay and longer recovery times. Severe grades of AKI were associated with progression to AKD, need for dialysis, and higher mortality. It is imperative to focus on interventions to minimize and address the risk factors to reduce morbidity and mortality associated with AKI in CPB surgery.

Drug Resistance in HIV Following First-line ART Failure: Insights from a Cross-sectional Study in India.

Arora S, Basavaraj P, Ashta KK … +2 more , Anil Kumar A, Raman N

J Assoc Physicians India · 2026 Feb · PMID 41818070 · Publisher ↗

INTRODUCTION: Our study assesses human immunodeficiency virus (HIV) drug resistance (HIVDR) in patients failing first-line (1L) antiretroviral therapy (ART) with dual nucleoside analog reverse transcriptase inhibitor (NR... INTRODUCTION: Our study assesses human immunodeficiency virus (HIV) drug resistance (HIVDR) in patients failing first-line (1L) antiretroviral therapy (ART) with dual nucleoside analog reverse transcriptase inhibitor (NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) regimens in India. METHODS: In this cross-sectional study, consecutive HIV-1-infected patients aged 13 years or older, failing 1L ART after at least 12 months exposure, underwent HIV genotyping and drug resistance testing (DRT) using the ViroSeq™ HIV-1 Genotyping System and the Stanford HIV-1 Database, with HIVDR classification based on a penalty score of ≥30. RESULTS: Among 115 eligible participants, 110 underwent DRT, revealing efavirenz (EFV) or nevirapine (NVP) resistance rates of 85.3% ( = 93/109) and 87.2% ( = 95/109), respectively, and substantial cross-resistance to rilpivirine (RPV) (37.6%, = 41/109), etravirine (ETV) (30.3%, = 33/109), and doravirine (DOR) (60.5%, = 66/109). The cohort was categorized into 3 groups based on their previous ARV drug exposure: group A (36.4%, = 40) with prior TA exposure (AZT or d4T) but no TFV exposure; group B (19.1%, = 21) with prior nonconcomitant exposure to both TAs and TFV; and group C (44.5%, = 49), exposed to TFV only. Despite group B's 1L ART regimen failure with TFV, the prevalence of AZT resistance was similar (difference in proportions, ∇P: 14.6%, = 0.277) between group A [57.5% ( = 23/40)] and group B [42.9% ( = 9/21)]. TFV resistance was comparable (∇P: 0.8%, = 0.947) between group A (32.5%, = 13/40) and group B (33.3%, = 7/21), despite group A's lack of TFV exposure, and was also similar to the TFV-only-exposed group (group C: 38.8%, = 19/49). Regarding distinct DRM patterns, the prevalence of K65R DRM was higher (∇P: 22.4%, = 0.060) among TFV-only-exposed patients (group C: 36.7%, = 18/49) compared with PLH exposed to both TAs and TFV (group B: 14.3%, = 3/21), whereas multiple TAMs occurred at similar rates (∇P: 12.1%, = 0.367) among TA-exposed patients [group A: 55.0% ( = 22/40) vs group B: 42.9% ( = 9/21)]. CONCLUSION: The research provides insights into the complexities of HIVDR, emphasizing the interplay of resistance patterns and the role of drug exposure history, especially in the context of resistance to TFV and second-generation NNRTIs. CLINICAL SIGNIFICANCE: Ensuring adequate drug exposure history in patients can prevent poor outcomes in PLH being treated with ART due to resistance. Resistance profiling is especially relevant following first-line ART failure.

Lipoprotein(a) Augments Coronary Risk Estimation in Type 2 Diabetes: A Cross-sectional Study.

Sharma S, Chandak RK, Sharma KK … +2 more , Guptha S, Gupta R

J Assoc Physicians India · 2026 Feb · PMID 41818069 · Publisher ↗

OBJECTIVE: Risk estimation tools have been developed to predict coronary heart disease (CHD) in type 2 diabetes (T2D). To evaluate augmentation following the addition of lipoprotein(a) [Lp(a)] to risk calculation, we per... OBJECTIVE: Risk estimation tools have been developed to predict coronary heart disease (CHD) in type 2 diabetes (T2D). To evaluate augmentation following the addition of lipoprotein(a) [Lp(a)] to risk calculation, we performed a pilot study. METHODS: A total of 90 successive T2D patients were included. Details of clinical and biochemical features were obtained. Lp(a) was determined using ELISA. CHD risk estimation was performed using Framingham, QRISK-3, SCORE-2D, INTERHEART, and European Atherosclerosis Society (EAS) algorithms with and without Lp(a). Descriptive statistics are reported. RESULTS: Mean age of patients was 55.0 ± 8 years, BP systolic/diastolic 133.7 ± 12/95.0 ± 9 mm Hg, body mass index (BMI) 26.0 ± 1.9 kg/m, waist-hip ratio 0.96 ± 0.08, fasting glucose 198.0 ± 38 mg/dL, HbA1c 9.3 ± 1.3%, total cholesterol 197.0 ± 26 mg/dL, LDL cholesterol 114.2 ± 25 mg/dL, non-HDL cholesterol 153.8 ± 27 mg/dL, and triglycerides 197.8 ± 44 mg/dL. Lp(a) was mean 23.1 ± 9.7 mg/dL and median 22.0 (25-75 IQR 15.9-29.5) mg/dL. Mean risk scores were Framingham 11.2 ± 8.7, QRISK-3 28.6 ± 15.3, INTERHEART 21.0 ± 6.0, SCORE-2D 14.9 ± 8.3, and EAS 29.2 ± 15.2. Patients with raised Lp(a) >30 mg/dL had higher levels of total, LDL, and non-HDL cholesterol and triglycerides ( < 0.01). Spearman's correlation of Lp(a) with risk scores was Framingham 0.127, QRISK-3 0.174, INTERHEART 0.137, SCORE-2D 0.050, and EAS 0.320, while EAS-Lp(a) was 0.397. In different risk algorithms, high risk for CHD were: Framingham 14.4%, QRISK-3 64.4%, INTERHEART 45.6%, SCORE-2D 30.0%, EAS 71.1%, and EAS with Lp(a) 74.4%. Area under the curve (AUC) for Lp(a) with various scores were Framingham 0.53 (CI: 0.39-0.68; = 0.644), QRISK-3 0.57 (CI: 0.42-0.71), INTERHEART 0.55 (CI: 0.39-0.69), SCORE-2D 0.47 (CI: 0.32-0.61), EAS 0.65 (CI: 0.50-0.79), and EAS-Lp(a) 0.68 (CI: 0.54-0.83). In addition, adding Lp(a) to the EAS risk calculator increased risk reclassification by a range of 4.6-19.3%. CONCLUSION: Substantial variation in coronary artery disease (CAD) risk prediction using various clinical algorithms is observed in T2D. The EAS algorithm provides the most robust estimate. The addition of Lp(a) to the risk algorithms augments risk stratification significantly. The results of this pilot study need confirmation with larger prospective studies.

Clinical and Laboratory Profile of Patients with Tropical Coinfections Admitted at a Tertiary Care Center in North India.

Kaur A, Gupta M, Singla N … +2 more , Lehl SS, Attri S

J Assoc Physicians India · 2026 Feb · PMID 41818068 · Publisher ↗

BACKGROUND: Tropical coinfections (CI) are the simultaneous occurrence of two or more vector-borne diseases in a single host. The prevalence of such illnesses is not uncommon among tropical and subtropical regions such a... BACKGROUND: Tropical coinfections (CI) are the simultaneous occurrence of two or more vector-borne diseases in a single host. The prevalence of such illnesses is not uncommon among tropical and subtropical regions such as India; however, these CIs have not been systematically studied prospectively. Mixed infections can prove potentially detrimental if underdiagnosed or undertreated. We undertook this study to estimate the prevalence and compare the clinical profile, laboratory characteristics, and various outcomes among the patients with tropical CI who presented with acute undifferentiated febrile illness (AUFI). MATERIALS AND METHODS: A prospective, observational study was conducted on adult patients hospitalized with tropical CIs. As per the clinical suspicion, a panel of tests for dengue fever (D), malaria (M), scrub typhus (S), leptospirosis (L), chikungunya (C), and brucella (B) was carried out. Statistical analysis was done using standard methods. RESULTS: The mean age of the population was 39.4 ± 17.3 years. Among 986 patients presenting with AUFI, 8.1% of the patients had CIs. Of these CIs, 95% had dual infections, and 5% had CIs with three tropical pathogens. We observed 17 diverse tropical CI combinations; four predominant being D + L, D + S, D + C, and S + L with a prevalence of 26.2, 25, 15, and 13.8%, respectively. 16.25% of the patients with tropical CIs died, mostly those suffering from D + S and D + L. Coinfection with D + S had predominant acute kidney injury (AKI), whereas acute transaminitis was highest in the D + L category. Acute respiratory distress syndrome (ARDS) was clinically significant in S + L, and multiorgan dysfunction was highest in the D + S combination. Using logistic regression, AKI, hepatitis, ARDS, shock, gastrointestinal bleeding, and myocarditis were independent risk factors for mortality. CONCLUSION: Our study identified 17 different combinations of CIs. Four groups, i.e., D + L, D + S, D + C, and S + L-accounted for 80% of CIs. Despite significant organ involvement in certain CI combinations, we conclude that a clinical bedside differentiation of tropical CIs from monomicrobial infections is often difficult. Hence, optimal treatment for a possible CI may well be commenced empirically and early, bearing in mind an 8% probability of a concurrent tropical coinfection.

Circadian Rhythm Disruption and Osteoporosis in Postmenopausal Women: An Observational Study from a Tertiary Care Center in India.

Gupta P, Sharma A, Chaurasia AK … +1 more , Mathur M

J Assoc Physicians India · 2026 Feb · PMID 41818067 · Publisher ↗

BACKGROUND: Osteoporosis, a common bone disease among postmenopausal women, where bone is weak by diminished bone mineral density (BMD), increasing the fracture risk. Our body's natural rhythm, called the "circadian rhyt... BACKGROUND: Osteoporosis, a common bone disease among postmenopausal women, where bone is weak by diminished bone mineral density (BMD), increasing the fracture risk. Our body's natural rhythm, called the "circadian rhythm," which is controlled by the brain and body, helps in bone formation and also in breakdown, disruption of this rhythm may affect bone health. This study explores how problems with circadian rhythm might be linked with osteoporosis in postmenopausal women. OBJECTIVE: To assess the prevalence of osteoporosis among postmenopausal women and to see if it is related to changes in their body's daily sleep-wake cycle, "circadian rhythm," using a composite morningness-eveningness questionnaire (CMEQ) that groups people as morning, evening, or in between types. MATERIALS AND METHODS: This cross-sectional observational study was conducted at Swaroop Rani Hospital, Prayagraj, India, between March 2024 and March 2025. This study included 109 postmenopausal women after applying strict inclusion/exclusion criteria. Each woman underwent clinical evaluation, anthropometric measurements, and biochemical testing. BMD by dual-energy X-ray absorptiometry (DEXA) scan at the lumbar spine with right and left femoral necks. To understand their sleep-wake pattern, "circadian rhythm" participants filled out a special questionnaire called the CMEQ, which groups them as morning, evening, or in between types. Data was analyzed using computer software (SPSS v25.0) to find patterns and differences. RESULTS: The prevalence of osteoporosis was 32.1% (35 among 109 women). Osteoporotic women had significantly lower weight (58.1 ± 11.63 vs 64.3 ± 13.65 kg; = 0.023) and height (149.1 ± 7.12 cm vs 153.0 ± 7.08 cm; = 0.008) compared to nonosteoporotic participants. Body mass index (BMI) was lower in the osteoporotic group (26.3 vs 28.1), though not statistically significant ( = 0.093). The mean composite M-E score did not have a significant value between osteoporotic and nonosteoporotic groups (44.8 ± 3.55 vs 44.6 ± 4.23; = 0.852), indicating no significant association between circadian rhythm and osteoporosis. CONCLUSION: About one-third of postmenopausal women in the study had osteoporosis. Although anthropometric differences were significant, no statistical significance was found between circadian rhythm and BMD. The findings suggest that circadian rhythm may affect bone health, but the questionnaires CMEQ used in this study may not be the best way to measure it. Future studies should use more accurate measures of taste, such as circadian hormone levels, and follow people over time to better understand this relationship.

Educating for Equity: The Role of Educational Intervention in Shaping Health Care Students' Knowledge of Universal Health Coverage and Primary Health Care.

Daniel RS, Patil SS, Doddihal C … +1 more , Sorganvi V

J Assoc Physicians India · 2026 Feb · PMID 41818066 · Publisher ↗

BACKGROUND: Universal health coverage (UHC) and primary health care (PHC) are critical components of equitable health systems. Medical and allied health science students, as future healthcare providers, need to possess k... BACKGROUND: Universal health coverage (UHC) and primary health care (PHC) are critical components of equitable health systems. Medical and allied health science students, as future healthcare providers, need to possess knowledge and understanding of these concepts. Educational interventions are pivotal in enhancing this knowledge and preparing students for effective healthcare delivery. OBJECTIVES: This study aimed to assess the impact of an educational intervention on the knowledge and perception of UHC and PHC among healthcare students at a private medical university in north Karnataka. METHODOLOGY: A quasi-experimental study design was employed involving 300 healthcare students during June-August 2024. The study comprised 3 phases: a pretest to gauge baseline knowledge about UHC and PHC. An educational session focused on UHC and PHC was conducted, and a posttest to evaluate the knowledge acquired was done. The pretest and posttest consisted of a 23-item questionnaire. Statistical analysis comprised the Kruskal-Wallis and Wilcoxon signed ranks tests to compare pre- and postintervention knowledge scores. RESULTS: The pretest results indicated a mean knowledge score of ±8.07. Following the educational intervention, the posttest results revealed a significant increase in knowledge, with a mean score of ±13.8. This positive outcome emphasizes the effectiveness of the educational intervention. CONCLUSION: The study demonstrates that targeted educational interventions can significantly improve the knowledge of UHC and PHC among healthcare students. Incorporating regular educational programs, including practical seminars on UHC and PHC, in their study curricula is recommended to sustain and enhance this knowledge.

A Study to Assess the Prevalence, Risk Factors, and Role of Epicardial Fat Thickness in Prediction of Diabetic Retinopathy in Type 2 Diabetic Patients in a Tertiary Care Center in Western Uttar Pradesh.

Shekhar S, Gautam S, Mittal C … +3 more , Verma S, Garg P, Pandey CB

J Assoc Physicians India · 2026 Feb · PMID 41818065 · Publisher ↗

INTRODUCTION: Diabetic retinopathy (DR) is the most important risk factor causing blindness in diabetic individuals, and its risk progresses with increased disease duration. Epicardial fat thickness (EFT) is an emerging... INTRODUCTION: Diabetic retinopathy (DR) is the most important risk factor causing blindness in diabetic individuals, and its risk progresses with increased disease duration. Epicardial fat thickness (EFT) is an emerging indicator of inflammation and metabolic derangement and has been proposed as a potential biomarker linked to the severity of DR. This study aims to assess the prevalence of DR, identify risk factors associated with DR, and evaluate the predictive role of EFT in detecting DR in subjects with type 2 diabetes mellitus (T2DM). METHODS: A cross-sectional observational study was conducted at LLRM Medical College, Meerut, from 2023 to 2024. The participants included 130 T2DM patients who were assessed clinically, radiologically, and biochemically. Demographic data, duration of diabetes, body mass index (BMI), HbA1c levels, and EFT were measured. The severity of DR was determined based on ophthalmic examination. Data were analyzed using Kruskal-Wallis and Chi-squared tests. RESULTS: In this study of 130 patients with T2DM, 64.61% ( = 84) had DR, including 33.84% ( = 44) with nonproliferative DR (NPDR) and 30.76% ( = 40) with proliferative DR (PDR), while 35.38% ( = 46) had no DR. Patients in the PDR group were older on average (60.5 ± 13.9 years), but age differences were not statistically significant ( = 0.154). The duration of diabetes was significantly longer in PDR patients (9.0 ± 3.01 years) compared with NPDR and non-DR groups ( < 0.001). BMI increased with DR severity, reaching 28.49 ± 2.07 kg/m in the PDR group, in which 20% were obese and 72.5% were overweight. A higher waist-hip ratio (WHR) was significantly associated with more severe DR in males ( < 0.001) but not in females ( = 0.099). HbA1c levels increased with disease severity, from 6.1 ± 0.71% in non-DR to 8.6 ± 1.97% in PDR patients ( < 0.001). Similarly, EFT increased from 3.9 ± 0.47 mm in non-DR to 7.9 ± 1.09 mm in PDR ( < 0.001), suggesting EFT as a potential biomarker for DR severity. These findings highlight strong links between DR severity, poor glycemic control, obesity measures, and longer diabetes duration. CONCLUSION: These findings suggest that in type 2 diabetes mellitus patients, EFT can serve as a significant marker for the severity of DR. It can be used as a noninvasive investigation to predict PDR. When considered alongside established risk factors such as BMI, HbA1c levels, and diabetes duration, EFT could enhance early identification of patients at risk, potentially helping to prevent advancement to the more severe proliferative stage (PDR). However, larger and more extensive studies are required to confirm these observations and strengthen their clinical relevance.

Diversity, Equity, and Inclusivity-The Trident of Destiny.

Chatterjee N

J Assoc Physicians India · 2026 Feb · PMID 41818064 · Publisher ↗

Chatterjee N. Diversity, Equity, and Inclusivity-The Trident of Destiny. J Assoc Physicians India 2026;74(2):11. Chatterjee N. Diversity, Equity, and Inclusivity-The Trident of Destiny. J Assoc Physicians India 2026;74(2):11.

Future Directions and Innovations in Mineralocorticoid Receptor Antagonist Therapy.

Joshi S, Tiwaskar M, Sharma J … +11 more , Kunhali K, Rastogi V, Antony S, Nandhakumar AP, Vora A, Raja AG, Anitha A, Parmar RS, Francis F, Sugumaran A, Mohanasundaram S

J Assoc Physicians India · 2026 Jan · PMID 41818055 · Publisher ↗

Mineralocorticoid receptor antagonists (MRAs) are important pillars in the treatment of heart failure (HF), chronic kidney disease (CKD), and diabetic kidney disease (DKD). MRAs share complementary pathways with sodium-g... Mineralocorticoid receptor antagonists (MRAs) are important pillars in the treatment of heart failure (HF), chronic kidney disease (CKD), and diabetic kidney disease (DKD). MRAs share complementary pathways with sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with cardiovascular-kidney-metabolic (CKM) syndrome. Combination therapies of MRA with SGLT2i and GLP-1RA are showing promising results in CKM than individual therapies. Further, the unique action of MRAs in antagonizing MR receptors and aldosterone, implicated in the pathophysiology of several conditions, is paving the way for clinical trials and promising results in these therapeutic areas. Disease-specific biomarkers such as UACR and eGFR are increasingly being used to individualize treatment with MRA. Utilizing MRA-specific biomarkers may open the path for precision medicine and further treatment individualization.

Mineralocorticoid Receptor Antagonist and Its Combinations in Heart Failure.

Varghese K, George J, Khanna R … +11 more , Rath JK, Sinha KK, Dargad R, Gutghe S, Shah T, Ganatra L, Bhatt S, Jain DK, Francis F, Sugumaran A, Mohanasundaram S

J Assoc Physicians India · 2026 Jan · PMID 41818054 · Publisher ↗

Mineralocorticoid receptor antagonists (MRAs) are strongly recommended by various guidelines for the management of patients with heart failure. Present and emerging clinical evidence also supports the beneficial role of... Mineralocorticoid receptor antagonists (MRAs) are strongly recommended by various guidelines for the management of patients with heart failure. Present and emerging clinical evidence also supports the beneficial role of MRAs in lowering the risk of heart failure-associated hospitalization and mortality. Loop diuretics play a crucial role in the management of edema associated with heart failure; however, their use has been associated with electrolyte abnormalities, activation of the renin-angiotensin-aldosterone and sympathetic systems, and diuretic resistance. Combined use of loop diuretics along with MRAs can help to overcome the diuretic resistance and improve the efficacy and safety of loop diuretics. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are another class of drugs that have shown significant benefits in patients with heart failure and are guideline-recommended for use in these patients. Combination therapy of SGLT2 inhibitors along with MRAs can improve various clinical outcomes in heart failure patients and reduce the risk of hyperkalemia, commonly associated with MRA therapy. Combination therapies can be potential opportunities to improve clinical outcomes and patient adherence in the management of patients with heart failure.

Risk of Delaying or Omitting Mineralocorticoid Receptor Antagonists in Heart Failure.

Lal M, Kumar M, Kancharla R … +11 more , Singh S, Kumar A, Sutaria M, Patel BM, Maniar HB, Haris SV, Maheshwari B, Singh SK, Francis F, Sugumaran A, Mohanasundaram S

J Assoc Physicians India · 2026 Jan · PMID 41818053 · Publisher ↗

Despite strong class I, level A recommendations from major clinical guidelines, the early initiation and optimization of mineralocorticoid receptor antagonists (MRAs) in heart failure (HF) with reduced ejection fraction... Despite strong class I, level A recommendations from major clinical guidelines, the early initiation and optimization of mineralocorticoid receptor antagonists (MRAs) in heart failure (HF) with reduced ejection fraction (HFrEF) remain suboptimal. MRAs, including spironolactone and eplerenone, provide significant morbidity and mortality benefits, particularly when introduced early in high-risk scenarios such as acute myocardial infarction (AMI) and acute decompensated heart failure (ADHF). Evidence from landmark trials and real-world registries underscores that early MRA therapy reduces cardiovascular events, prevents adverse ventricular remodeling, and lowers sudden cardiac death risk. Delaying or omitting MRAs, even by a few weeks, is associated with increased mortality, recurrent hospitalizations, and irreversible cardiac damage. Clinical evidence demonstrated that early aldosterone blockade exerts rapid and sustained benefits, often within days of initiation. Early initiation and aggressive optimization of MRAs must be prioritized in HFrEF management to fully realize their life-saving potential.

Early Initiation and Dose Optimization of Mineralocorticoid Receptor Antagonists in Heart Failure.

Banerjee S, Rajput R, Shah C … +11 more , Raghunandan BK, Gupta A, Chatterjee S, Anne KP, Veer A, Joshi A, Raghuvanshi A, Kedarnathan R, Francis F, Sugumaran A, Mohanasundaram S

J Assoc Physicians India · 2026 Jan · PMID 41818052 · Publisher ↗

Guidelines recommend that the foundation four guideline-directed medical therapy (GDMT), which includes mineralocorticoid receptor antagonists (MRAs), should be initiated early in the treatment paradigm of heart failure... Guidelines recommend that the foundation four guideline-directed medical therapy (GDMT), which includes mineralocorticoid receptor antagonists (MRAs), should be initiated early in the treatment paradigm of heart failure due to mortality benefits and reduction in hospitalization for heart failure. However, the practical implementation of these guidelines in the real-world clinical scenario is lacking. Delay in initiating MRA is common, and patients often do not receive the optimum dose of MRA. The clinical considerations and guideline recommendations for early initiation and optimum dosing of MRA in HF can form the scientific basis for improving the correct usage of MRA in HF in real-world settings.

Tackling Therapeutic Inertia on Mineralocorticoid Receptor Antagonist Adoption in Heart Failure.

Jaswal A, Ghose T, Aggarwal A … +11 more , Singh AK, Chakravarty N, Roy R, D S A, Patel DC, Sankhla M, Anitha M, Patel D, Francis F, Sugumaran A, Mohanasundaram S

J Assoc Physicians India · 2026 Jan · PMID 41818051 · Publisher ↗

Clinical inertia is a major cause of mineralocorticoid receptor antagonist (MRA) underuse and failure to intensify MRA dose in heart failure (HF). Hyperkalemia and worsening of renal function are the main causes of clini... Clinical inertia is a major cause of mineralocorticoid receptor antagonist (MRA) underuse and failure to intensify MRA dose in heart failure (HF). Hyperkalemia and worsening of renal function are the main causes of clinical inertia seen with MRA. However, evidence shows that the risk of hyperkalemia is not very high with MRA use, and patients often die due to MRA withdrawal rather than hyperkalemia itself. Hence, addressing this fear of hyperkalemia is important to improve MRA prescription and patient outcomes. Other androgenic side effects of MRAs should also be managed for better adoption of this guideline-directed medical therapy in HF.

Real-world Utilization of Mineralocorticoid Receptor Antagonists in India and the Benefits of GDMT in Heart Failure.

Gautam N, Chowdhury PD, Batta A … +11 more , Gupta RK, Kannodia N, Prabhakar KK, Munichoodappa K, Shah M, Durve K, Nadeem M, Mohan V, Francis F, Sugumaran A, Mohanasundaram S

J Assoc Physicians India · 2026 Jan · PMID 41818050 · Publisher ↗

Early initiation of guideline-directed medical therapies (GDMTs) in heart failure (HF) and their uptitration to the target dose confer mortality benefits and reduce the risk of readmission. GDMT nonuse is a significant p... Early initiation of guideline-directed medical therapies (GDMTs) in heart failure (HF) and their uptitration to the target dose confer mortality benefits and reduce the risk of readmission. GDMT nonuse is a significant predictor of mortality in HF patients. However, GDMT prescription and adherence in India are low. Of the GDMTs, mineralocorticoid receptor antagonists (MRAs) are the least prescribed. There are multilevel gaps [healthcare professional (HCP)-related, patient-related] in the adoption and use of MRAs in HF. There is an unmet need to identify these gaps and formulate mitigation strategies to close them. This can improve or enhance GDMT adoption in the HF treatment paradigm.

Mineralocorticoid Receptor Antagonists: The Pillar Drug in Heart Failure.

Sethi R, Jain R, Raj RA … +10 more , Jaya PV, Arora M, Thakran V, Pandey RK, Sharma J, Rao KMM, Sharma H, Francis F, Sugumaran A, Mohanasundaram S

J Assoc Physicians India · 2026 Jan · PMID 41818049 · Publisher ↗

Mineralocorticoid receptor antagonists (MRAs) have emerged as a cornerstone in the pharmacological management of heart failure (HF), particularly in patients with reduced ejection fraction (HFrEF). By antagonizing the ef... Mineralocorticoid receptor antagonists (MRAs) have emerged as a cornerstone in the pharmacological management of heart failure (HF), particularly in patients with reduced ejection fraction (HFrEF). By antagonizing the effects of aldosterone, MRAs mitigate fluid retention, myocardial fibrosis, and neurohormonal activation, key contributors to HF progression. Steroidal MRAs, including spironolactone and eplerenone, have demonstrated significant clinical efficacy in landmark trials such as Randomized Aldactone Evaluation Study (RALES), Eplerenone Postacute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), and Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), showing reductions in mortality, hospitalizations, and symptomatic burden. Spironolactone, though potent, is associated with hormonal side effects due to its nonselective receptor binding, while eplerenone offers improved tolerability through greater receptor specificity. This review explores the pharmacological mechanisms, clinical trial evidence, and safety considerations of steroidal MRAs, underscoring their indispensable role in comprehensive HF therapy.

The Pharmacological Properties and Safety Profile of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction.

Solanki D, Badani R, Tiwaskar M … +11 more , Sandeep S, Bhalla N, Nadeem M, Garg V, Reddy PK, Kamat S, Joshi PK, Raja AG, Francis F, Sugumaran A, Mohanasundaram S

J Assoc Physicians India · 2026 Jan · PMID 41818048 · Publisher ↗

Among the established mineralocorticoid receptor antagonists (MRAs), spironolactone and eplerenone have demonstrated significant clinical utility in managing conditions such as chronic heart failure, resistant hypertensi... Among the established mineralocorticoid receptor antagonists (MRAs), spironolactone and eplerenone have demonstrated significant clinical utility in managing conditions such as chronic heart failure, resistant hypertension, and hyperaldosteronism. Spironolactone, the first steroidal MRA, is known for its broad receptor affinity, contributing to both therapeutic benefits and endocrine-related side effects. Eplerenone, a more selective agent, offers improved tolerability with reduced hormonal adverse effects. This review explores the pharmacokinetic and pharmacodynamic profiles of these agents, highlighting their mechanisms of action, receptor-binding characteristics, and clinical implications. The safety considerations associated with long-term use, particularly hyperkalemia and renal function impairment, are also discussed to provide a comprehensive understanding of their therapeutic roles.

The Mechanism of Action of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction.

Mantri RR, Vora A, Hasan A … +11 more , Raval A, Kumar RS, Gupta SK, Chatterjee S, Srinivas SV, Chandra K, Krishnamoorthy S, Junaidy KH, Francis F, Sugumaran A, Mohanasundaram S

J Assoc Physicians India · 2026 Jan · PMID 41818047 · Publisher ↗

Mineralocorticoid receptor antagonists (MRAs) are one of the guideline-directed medical therapies for patients with heart failure and chronic kidney disease due to their anti-inflammatory and antifibrotic effects. MRAs r... Mineralocorticoid receptor antagonists (MRAs) are one of the guideline-directed medical therapies for patients with heart failure and chronic kidney disease due to their anti-inflammatory and antifibrotic effects. MRAs regulate mineralocorticoid receptor (MR) signaling by inhibiting aldosterone binding to MR. MRAs are classified into steroidal and nonsteroidal categories based on their molecular interactions and clinical applications. Steroidal MRAs have been widely used in clinical practice and have demonstrated significant efficacy. Continuous advancements in the field have led to the development of nonsteroidal MRAs with greater receptor selectivity and better safety profile.

Mineralocorticoid Receptor Antagonists: An Overview of History and Evolution.

Kalmath BC, Tiwaskar M, Kumar GR … +11 more , Khemani H, Singh A, Kishore R, Chouhan A, Harikrishnan BL, Choudhary S, Goyal M, Pradhan A, Francis F, Sugumaran A, Mohanasundaram S

J Assoc Physicians India · 2026 Jan · PMID 41818046 · Publisher ↗

Mineralocorticoid receptor antagonists (MRAs) have significantly evolved since the introduction of the first steroidal MRA, spironolactone, in the 1950s. Initially discovered for treating hypertension and heart failure (... Mineralocorticoid receptor antagonists (MRAs) have significantly evolved since the introduction of the first steroidal MRA, spironolactone, in the 1950s. Initially discovered for treating hypertension and heart failure (HF), the clinical applications of MRAs have been expanded to chronic kidney disease (CKD) and diabetic nephropathy. Steroidal MRAs, such as spironolactone and eplerenone, effectively suppress mineralocorticoid receptor activation but are associated with side effects like hyperkalemia and endocrine abnormalities. Current research aims to optimize MRAs further for broader therapeutic applications, including nondiabetic kidney and cardiovascular diseases, and to improve safety profiles. In this review, we reflect on the historical development, classification, evolution, major clinical trials, and future prospects of MRAs.

Preface.

Gogtay J

J Assoc Physicians India · 2026 Jan · PMID 41818044 · Publisher ↗

Gogtay J. Preface. J Assoc Physicians India 2026;74(1):7-7. Gogtay J. Preface. J Assoc Physicians India 2026;74(1):7-7.

Guest Editorial.

Bansal S

J Assoc Physicians India · 2026 Jan · PMID 41818043 · Publisher ↗

Bansal S. Guest Editorial. J Assoc Physicians India 2026;74(1):6-6. Bansal S. Guest Editorial. J Assoc Physicians India 2026;74(1):6-6.
← Prev Page 5 of 10 Next →

About

Frequency
Sun
Papers found
200
RSS feed
Subscribe